Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Apr 05, 2019 9:13am

105 Views

Post# 29586545

RE:Weekly Trogarzo Sales - looking good

Thanks SPCEO.

Any new analyst reports out there this am?

bfw

SPCEO1 wrote: Once again, we saw that Bloomberg is often very wrong when 1Q Trogarzo came in officially at +44% when Bloomberg had suggested more like a 30% gain. But, we can hope they are pretty close to being accurate this week since they came in at a new record weekly high and were 24% above the previous record weekly high. For the first four weeks in Q2, Trogarzo sales were 50% higher than the first 4 weeks in Q1.

I think our new head of sales is having a positive impact.

Bullboard Posts

Golden Minerals closes Yoquivo gold-silver project sale